These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15007871)

  • 21. [Bacterial airway infections. Standard antibiotics more often ineffective].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910829
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections.
    Nord CE; Farrell DJ; Leclercq R
    Microb Drug Resist; 2004; 10(3):255-63. PubMed ID: 15383171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.
    Magee TV; Ripp SL; Li B; Buzon RA; Chupak L; Dougherty TJ; Finegan SM; Girard D; Hagen AE; Falcone MJ; Farley KA; Granskog K; Hardink JR; Huband MD; Kamicker BJ; Kaneko T; Knickerbocker MJ; Liras JL; Marra A; Medina I; Nguyen TT; Noe MC; Obach RS; O'Donnell JP; Penzien JB; Reilly UD; Schafer JR; Shen Y; Stone GG; Strelevitz TJ; Sun J; Tait-Kamradt A; Vaz AD; Whipple DA; Widlicka DW; Wishka DG; Wolkowski JP; Flanagan ME
    J Med Chem; 2009 Dec; 52(23):7446-57. PubMed ID: 19775168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Resistance of respiratory tract infection agents is still increasing. Is its time for new antibiotic strategies?].
    MMW Fortschr Med; 2003 Feb; 145(9):55. PubMed ID: 12666535
    [No Abstract]   [Full Text] [Related]  

  • 25. [A new antibiotic against respiratory tract infections. More power against pneumococci].
    MMW Fortschr Med; 2001 Nov; 143(44):59. PubMed ID: 11732406
    [No Abstract]   [Full Text] [Related]  

  • 26. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PROTEKT US: results from the second year of this longitudinal surveillance study of antimicrobial resistance among respiratory tract pathogens isolated from paediatric and adult patients in the USA. Introduction.
    Brown SD
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i5. PubMed ID: 15352301
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.
    Nicolau DP
    Expert Opin Pharmacother; 2004 Feb; 5(2):229-35. PubMed ID: 14996620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Telithromycin in the management of lower respiratory tract infections in the hospital].
    Léophonte P
    Presse Med; 2003 Jun; 32(20):952-3. PubMed ID: 12876542
    [No Abstract]   [Full Text] [Related]  

  • 31. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of telithromycin resistance in Streptococcus pneumoniae.
    Kaieda S; Okitsu N; Yano H; Hosaka Y; Nakano R; Okamoto R; Takahashi H; Inoue M
    J Antimicrob Chemother; 2003 Oct; 52(4):736-7. PubMed ID: 12951334
    [No Abstract]   [Full Text] [Related]  

  • 34. [Telithromycin].
    Calbo E; Garau J
    Rev Esp Quimioter; 2004 Mar; 17(1):15-25. PubMed ID: 15201919
    [No Abstract]   [Full Text] [Related]  

  • 35. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
    Low DE; Felmingham D; Brown SD; Rangaraju M; Nusrat R
    J Infect; 2004 Aug; 49(2):115-25. PubMed ID: 15236918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telithromycin: a brief review of a new ketolide antibiotic.
    Scheinfeld N
    J Drugs Dermatol; 2004; 3(4):409-13. PubMed ID: 15303785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential interaction between telithromycin and warfarin.
    Kolilekas L; Anagnostopoulos GK; Lampaditis I; Eleftheriadis I
    Ann Pharmacother; 2004 Sep; 38(9):1424-7. PubMed ID: 15280511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telithromycin. Aventis Pharma.
    Johnson AP
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.